ZIOPHARM Oncology Inc logo

ZIOP - ZIOPHARM Oncology Inc Share Price

$3.11 0.1  2.0%

Last Trade - 05/06/20

Sector
Healthcare
Size
Mid Cap
Market Cap £519.0m
Enterprise Value £383.2m
Revenue £n/a
Position in Universe 2638th / 6321
Bullish
Bearish
Unlock ZIOP Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Financial Summary
FINANCIAL BRIEF: : For the three months ended 31 March 2020, ZIOPHARM Oncology Inc. revenues was not reported. Net loss increased 36% to $18.3M. Higher net loss reflects Other Research and development increase of 35% to $12.2M (expense), Other General and Administrative increase of 46% to $4.5M (expense), Stock-based Compensation in SGA increase of 38% to $1.4M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.08 to -$0.09.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ZIOP Revenue Unlock ZIOP Revenue

Net Income

ZIOP Net Income Unlock ZIOP Revenue

Normalised EPS

ZIOP Normalised EPS Unlock ZIOP Revenue

PE Ratio Range

ZIOP PE Ratio Range Unlock ZIOP Revenue

Dividend Yield Range

ZIOP Dividend Yield Range Unlock ZIOP Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ZIOP EPS Forecasts Unlock ZIOP Revenue
Profile Summary

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.

Directors
Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated May 16, 2005
Public Since March 15, 2002
No. of Shareholders: 270
No. of Employees: 73
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 214,286,337
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ZIOP Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ZIOP
Upcoming Events for ZIOP
Monday 29th June, 2020
ZIOPHARM Oncology Inc Annual Shareholders Meeting
Frequently Asked Questions for ZIOPHARM Oncology Inc
What is the ZIOPHARM Oncology Inc share price?

As of 05/06/20, shares in ZIOPHARM Oncology Inc are trading at $3.11, giving the company a market capitalisation of £519.0m. This share price information is delayed by 15 minutes.

How has the ZIOPHARM Oncology Inc share price performed this year?

Shares in ZIOPHARM Oncology Inc are currently trading at $3.11 and the price has moved by -27.21% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the ZIOPHARM Oncology Inc price has moved by -33.72% over the past year.

What are the analyst and broker recommendations for ZIOPHARM Oncology Inc?

Of the analysts with advisory recommendations for ZIOPHARM Oncology Inc, there are there are currently 0 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for ZIOPHARM Oncology Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will ZIOPHARM Oncology Inc next release its financial results?

ZIOPHARM Oncology Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the ZIOPHARM Oncology Inc dividend yield?

ZIOPHARM Oncology Inc does not currently pay a dividend.

Does ZIOPHARM Oncology Inc pay a dividend?

ZIOPHARM Oncology Inc does not currently pay a dividend.

When does ZIOPHARM Oncology Inc next pay dividends?

ZIOPHARM Oncology Inc does not currently pay a dividend.

How do I buy ZIOPHARM Oncology Inc shares?

To buy shares in ZIOPHARM Oncology Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of ZIOPHARM Oncology Inc?

Shares in ZIOPHARM Oncology Inc are currently trading at $3.11, giving the company a market capitalisation of £519.0m.

Where are ZIOPHARM Oncology Inc shares listed? Where are ZIOPHARM Oncology Inc shares listed?

Here are the trading details for ZIOPHARM Oncology Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: ZIOP
What kind of share is ZIOPHARM Oncology Inc?

Based on an overall assessment of its quality, value and momentum, ZIOPHARM Oncology Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a ZIOPHARM Oncology Inc share price forecast 2020?

Shares in ZIOPHARM Oncology Inc are currently priced at $3.11. At that level they are trading at 88.52% discount to the analyst consensus target price of 0.00.

Analysts covering ZIOPHARM Oncology Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.372 for the next financial year.

How can I tell whether the ZIOPHARM Oncology Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ZIOPHARM Oncology Inc. Over the past six months, the relative strength of its shares against the market has been -40.64%. At the current price of $3.11, shares in ZIOPHARM Oncology Inc are trading at -20.93% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the ZIOPHARM Oncology Inc PE Ratio?

We were not able to find PE ratio data for ZIOPHARM Oncology Inc.

Who are the key directors of ZIOPHARM Oncology Inc?

ZIOPHARM Oncology Inc's management team is headed by:

Laurence Cooper - CEO
Scott Tarriff - CHM
Kevin Lafond - SVF
Elan Ezickson - IND
Lynn Ferrucci - EVP
Douglas Pagan - IND
Heidi Hagen - IND
Robert Hadfield - EVP
Scott Braunstein - IND
Satyavrat Shukla - CFO
Christopher Bowden - IND
Jill Buck - EVP
Eleanor De Groot - EVP
Who are the major shareholders of ZIOPHARM Oncology Inc?

Here are the top five shareholders of ZIOPHARM Oncology Inc based on the size of their shareholding:

The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 7.07% (15.2m shares)
MSD Partners, L.P. Investment Advisor
Percentage owned: 7.07% (15.2m shares)
White Rock Capital Management, L.P. Hedge Fund
Percentage owned: 6.11% (13.1m shares)
Miller Value Partners, LLC Investment Advisor
Percentage owned: 6% (12.9m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 5.47% (11.7m shares)
Similar to ZIOP
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.